title: Modeling cancer processes with CRISPR-Cas9.
abstract: CRISPR-Cas9 is an RNA-guided site-specific DNA editing tool which, together with its reprogrammed versions such as nickase Cas9 and dead Cas9, enables quick modeling of desired combinations of cancer-associated genomic and/or epigenetic aberrations simultaneously or sequentially, thus facilitating massive functional interrogations and therapy testing.
authors.affiliation: Department of Gastroenterology, Shanghai East Hospital, Tongji University, School of Medicine, Shanghai, China.
authors.forename: Xiao-Jie
authors.initials: XJ
authors.lastname: Lu
authors.affiliation: Biotherapy Center, Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China; Department of Gastroenterology and Hepatology, Tongji Hospital, Tongji University School of Medicine, Shanghai, China.
authors.forename: Xiaolong
authors.initials: X
authors.lastname: Qi
authors.affiliation: Department of Nephrology, The Second People's Hospital of Huai'an, Huai'an, China.
authors.forename: Dong-Hui
authors.initials: DH
authors.lastname: Zheng
authors.affiliation: Department of Rehabilitation, The Second People's Hospital of Huai'an, Huai'an, China. Electronic address: 189@whu.edu.cn.
authors.forename: Li-Juan
authors.initials: LJ
authors.lastname: Ji
mesh_terms: D064113:CRISPR-Cas Systems / Q000235:genetics*; D063646:Carcinogenesis / Q000235:genetics*; D015894:Genome, Human; D006801:Humans; D009154:Mutation; D009369:Neoplasms / Q000235:genetics* / Q000473:pathology; D017393:RNA Editing / Q000235:genetics*